Literature DB >> 17915217

Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway.

Shawn A Morales1, Sergey Mareninov, Pradeep Prasad, Madhuri Wadehra, Jonathan Braun, Lynn K Gordon.   

Abstract

Proliferative vitreoretinopathy (PVR) may result in part from de-differentiation of retinal pigment epithelium (RPE) in an aberrant wound-healing strategy. An in vitro model of PVR, collagen gel contraction by RPE, likely requires integrin engagement and activation as an important initial step. The purpose of this study was to identify the important associated integrins and signal transduction pathway. The retinal pigment epithelial cell line ARPE-19 was used in these studies. Cell surface integrin expression was assessed using flow cytometry. An in vitro contraction assay was performed and the percent contraction quantified at specific time intervals using image capture (Gel Doc) and NIH Image software. Cells were pretreated with either small molecule inhibitors of signal transduction pathways or monoclonal antibodies with specificity for specific integrin isoforms. Transient transfections with a FAK siRNA were used to decrease FAK expression. ARPE-19 cells express alpha1, alpha2, and alpha3 integrin, isoforms involved in collagen ligation. Cell surface integrin blockade using anti-integrin alpha2 (P=0.02), alpha3 (P=0.01), or a combination of alpha1, alpha2, and alpha3 (P=0.001) antibodies significantly reduced collagen gel contraction. Inhibition of the FAK-Src complex, but not MEK or PI3K, significantly decreased contraction (P=0.0001). FAK siRNA transient transfection significantly reduced FAK protein expression by 71% (P=0.02) and concordantly decreased gel contraction (P=0.0001). RPE-mediated collagen gel contraction is a multi-step process. Integrin ligation and FAK-Src activation is necessary for collagen gel contraction produced by the ARPE-19 cell line. Validation of these observations in primary RPE cells may suggest new targets for therapeutic intervention in PVR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17915217     DOI: 10.1016/j.exer.2007.08.014

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  18 in total

1.  Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Exp Eye Res       Date:  2012-06-19       Impact factor: 3.467

2.  Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2).

Authors:  Shawn A Morales; Sergey Mareninov; Paige Coulam; Madhuri Wadehra; Lee Goodglick; Jonathan Braun; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-03       Impact factor: 4.799

Review 3.  Regulation of FAK Activity by Tetraspan Proteins: Potential Clinical Implications in Cancer.

Authors:  Yu Qin; Shabnam Mohandessi; Lynn Gordon; Madhuri Wadehra
Journal:  Crit Rev Oncog       Date:  2015

4.  Epithelial membrane protein 2 controls VEGF expression in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Deanna Leon; Krisztina Forward; Jonathan Braun; Madhuri Wadehra; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-28       Impact factor: 4.799

5.  Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.

Authors:  Maoyong Fu; Erin L Maresh; Gustavo F Helguera; Meagan Kiyohara; Yu Qin; Negin Ashki; Tracy R Daniels-Wells; Najib Aziz; Lynn K Gordon; Jonathan Braun; Yahya Elshimali; Robert A Soslow; Manuel L Penichet; Lee Goodglick; Madhuri Wadehra
Journal:  Mol Cancer Ther       Date:  2014-01-21       Impact factor: 6.261

6.  Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-γ agonist.

Authors:  Kazuhiro Kimura; Tomoko Orita; Yang Liu; Yang Yang; Kazuhiro Tokuda; Taishi Kurakazu; Takeshi Noda; Ryoji Yanai; Naoyuki Morishige; Atsunobu Takeda; Tatsuro Ishibashi; Koh-Hei Sonoda
Journal:  J Mol Med (Berl)       Date:  2015-05-08       Impact factor: 4.599

7.  Rewiring integrin-mediated signaling and cellular response with the peripheral myelin protein 22 and epithelial membrane protein 2 components of the tetraspan web.

Authors:  Shawn A Morales; David Telander; Lucia Notterpek; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-23       Impact factor: 4.799

8.  A novel function of p53: a gatekeeper of retinal detachment.

Authors:  Hetian Lei; Marc-Andre Rheaume; Jing Cui; Shizuo Mukai; David Maberley; Arif Samad; Joanne Matsubara; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

9.  Progressive morphological and functional defects in retinas from alpha1 integrin-null mice.

Authors:  You-Wei Peng; Marisa Zallocchi; Daniel T Meehan; Duane Delimont; Bo Chang; Norman Hawes; Weimin Wang; Dominic Cosgrove
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-09       Impact factor: 4.799

10.  FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction.

Authors:  Shawn A Morales; Sergey Mareninov; Madhuri Wadehra; Lily Zhang; Lee Goodglick; Jonathan Braun; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.